Huntington’s disease, a rare genetic disorder characterized by diminishing brain function, has become an increasingly popular target for RNAi-based therapies. Sirna Therapeutics has been working in conjunction with the University of Iowa’s Beverly Davidson to develop a treatment for Huntington’s disease, while CytRx has said that it is considering starting up its own program for the disease.

Now Gustavo Tiscornia, of the Salk Institute for Biological Sciences in San Diego, is getting in on the game.